A PHASE 3, 8-WEEK, PARALLEL GROUP, DOUBLE BLIND, VEHICLE-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF ARQ-151 CREAM 0.3% ADMINISTERED QD IN SUBJECTS WITH CHRONIC PLAQUE PSORIASIS
- Registry ID
- ARQ-151-302
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- ARCUTIS BIOTHERAPEUTICS, INC
- Start date
- 2020-05-11
- Completion date
- 2020-11-17
- Last update
- 2019-12-20
Conditions
Related clinical trials
- MULTICENTER, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, PLACIEBO-CONTROLLED (12-17 YEARS) INCLUDING A SINGLE OPEN-LABEL ARM (6-11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO)
- A MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE SAFE AND EFFECTIVE USE OF THE PREFILLED SAFETY SYRINGES OR THE AUTO-INJECTOR FOR THE SUBCUTANEOUS SELF-INJECTION OF BIMEKIZUMAB SOLUTION BY SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
- A PHASE 3, MULTICENTER, RANDOMIZED, PLACEBO- AND ACTIVE COMPARATOR-CONTROLLED STUDY EVALUATING THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF SUBCUTANEOUSLY ADMINISTERED GUSELKUMAB FOR THE TREATMENT OF CHRONIC PLAQUE PSORIASIS IN PEDIATRIC SUBJECTS (¿6 TO <18 YEARS OF AGE)
- A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, SECUKINUIMAB-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PHASE 3B)
- A MULTICENTER, RANDOMIZED, SUBJECT-BLIND, INVESTIGATOR-BLIND STUDY TO EVALUATE THE TIME COURSE OF PHARMACODYNAMIC RESPONSE, SAFETY AND PHARMACOKINETICS OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS: PHASE 2A
- A MULTICENTER, 48-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS: PHASE 2B
View on source registry